Table 1.
Characteristic of included studies.
| Studies | Country | Study Design | Participant | Sample Size and Sex | Sample Size | Trial Duration (Week) |
Means Age | Means BMI | Intervention | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IG | CG | IG | CG | IG | CG | Intervention Dose (mg/d) | Control Group | ||||||
| Vafadar_afshar et al., 2020 | Iran | Parallel = l, R, PC, DB | Hemodialysis Patients | M/F (F:20, M:34) | 27 | 27 | 12 | 55.33 ± 12.95 | 59.05 ± 7.68 | 26.1 ± 5.19 | 27.19 ± 5.19 | 120 | placebo |
| Jazayeri-Tehrani et al., 2019 | Iran | parallel, R, PC, DB | non-alcoholic fatty liver disease | M/F (F:38, M:46) | 42 | 42 | 12 | 41.8 ± 5.6 | 42.5 ± 6.2 | 30.6 ± 2.14 | 30.7 ± 2.35 | 40 | placebo |
| Abdolahi et al., 2017 | Iran | parallel, R, PC, DB | migraine patients | M/F (F:30, M:8) | 19 | 19 | 8 | 37.36 ± 8.49 | 36.57 ± 8.15 | 27.59 ± 4.57 | 26.94 ± 3.87 | 80 | placebo |
| Rahimi et al., 2016 | Iran | parallel, R, PC, DB | type 2 diabetic | M/F (F:39, M:31) | 35 | 35 | 12 | 56.34 ± 11.17 | 60.95 ±1 0.77 | 26.92 ± 2.71 | 27.27 ± 3.59 | 80 | placebo |
| Osali. 2020 (A) | Iran | parallel, R, PC, DB | metabolic syndrome | F:22 | 11 | 6 | 6 | 62.3 ± 1.23 | 62.3 ± 1.23 | 31.24 ± 3.12 | 32.22 ± 2.46 | 80 | placebo |
| Osali. 2020 (B) | Iran | parallel, R, PC, DB | metabolic syndrome | F:22 | 11 | 5 | 6 | 62.3 ± 1.23 | 62.3 ± 1.23 | 29.54 ± 2.67 | 29.02 ± 1.56 | 80 | placebo |
| Asadi et al., 2019 | Iran | parallel, R, PC, DB | type 2 diabetes | M/F (F:70, M:10) | 40 | 40 | 8 | 53.3 ± 6.5 | 54.6 ± 6.2 | 31.1 ± 4.2 | 30.8 ± 3.8 | 80 | placebo |
| Bateni et al., 2021 | Iran | parallel, R, PC, DB | metabolic syndrome | M/F (F:33, M:10) | 22 | 21 | 12 | 50 ± 9 | 54 ± 7 | 29.9 ± 4.3 | 29.4 ± 4.5 | 80 | placebo |
| Abdolahi et al., 2018 (A) | Iran | parallel, R, PC, DB | Migraine | M/F (F:29, M:7) | 17 | 10 | 8 | 35.82 ± 8.2 | 36.15 ± 8.67 | 26.02 ± 4.04 | 26.16 ± 4.27 | 80 | placebo |
| Abdolahi et al., 2018 (B) | Iran | parallel, R, PC, DB | Migraine | M/F (F:30, M:8) | 19 | 9 | 8 | 37.36 ± 8.5 | 36.57 ± 8.15 | 27.59 ± 4.57 | 26.94 ± 3.87 | 80 | placebo |
| Shafabakhsh et al., 2020 | Iran | parallel, R, PC, DB | Diabetes on Hemodialysis | M/F (F:21, M:32) | 26 | 27 | 12 | 58.3 ± 9.4 | 56.2 ± 9.8 | 27.9 ± 4.9 | 27.1 ± 4.2 | 80 | placebo |
Abbreviations: IG, intervention group; CG, control group; DB, double-blinded; PC, placebo-controlled; CO, controlled; RA, randomized; NR, not reported; F, Female; M, Male.